Semax does something unusual for a small peptide: a single intranasal dose elevates brain-derived neurotrophic factor (BDNF) and its primary receptor TrkB in the hippocampus within 90 minutes, without binding any classical neurotransmitter receptor directly. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s and listed on Russia’s Essential Drugs List for stroke and cognitive disorders, this seven-amino-acid analog of adrenocorticotropic hormone has remained largely outside Western clinical practice despite decades of mechanistic and clinical research.
What Is Semax?
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, derived from the 4–7 fragment of adrenocorticotropic hormone (ACTH) with a C-terminal Pro-Gly-Pro extension that confers metabolic stability. The C-terminal tripeptide protects against rapid enzymatic degradation, extending the peptide’s half-life sufficiently for clinical use via intranasal administration.[1]
Critically, although Semax is derived from ACTH, it lacks the 1–3 N-terminal sequence required for melanocortin receptor activation and therefore has no corticotropic activity — it does not stimulate cortisol release. This separation of neurotropic from hormonal effects was the explicit design goal of the original Russian program led by Ashmarin and colleagues.[1]
How Semax Works
BDNF and TrkB Upregulation: The best-characterized effect of Semax is rapid induction of BDNF expression in the hippocampus and basal forebrain. In rodent studies, a single intranasal or intraperitoneal dose increases hippocampal BDNF mRNA and protein within 90 minutes, with parallel increases in TrkB receptor expression. This BDNF/TrkB axis is the principal substrate through which Semax is thought to exert cognitive and neuroprotective effects.[2]
Dopaminergic Modulation: Semax modulates dopaminergic and serotonergic systems indirectly. Microdialysis studies in rat striatum show that Semax administration alters extracellular dopamine and its metabolites (DOPAC, HVA), and the peptide influences activity of enkephalin-degrading enzymes, prolonging the action of endogenous opioid peptides that themselves modulate dopaminergic tone.[3]
Neurotrophic Gene Expression: Transcriptomic analyses of rat brain following Semax administration reveal coordinated changes in genes related to vascular development, immune response, and neurogenesis. The peptide upregulates expression of nerve growth factor (NGF) alongside BDNF, suggesting a broader neurotrophic program rather than a single-target mechanism.[2]
Anti-inflammatory and Antioxidant Effects: In models of cerebral ischemia, Semax reduces expression of pro-inflammatory genes and limits oxidative damage in penumbral tissue. This is thought to contribute to the clinical signal observed in acute ischemic stroke, where the therapeutic window depends on rescuing metabolically compromised but still viable neurons.[4]
Pharmacokinetics and Intranasal Delivery
Semax is administered intranasally, exploiting the olfactory and trigeminal pathways for direct nose-to-brain transport. This route bypasses first-pass hepatic metabolism and achieves measurable peptide concentrations in cerebrospinal fluid within minutes. The Pro-Gly-Pro C-terminal extension extends plasma half-life from the seconds typical of native ACTH fragments to a range that supports once- or twice-daily dosing.[1]
Behavioral effects in animal models persist well beyond the peptide’s measurable presence in tissue, consistent with the mechanism being initiation of a transcriptional program (BDNF, NGF, immediate-early genes) rather than ongoing receptor occupancy.
Clinical Evidence
Ischemic Stroke: Semax has been studied most extensively as an adjunct in acute ischemic stroke, where it is registered for clinical use in Russia. Clinical trials have reported improvements in neurological recovery scores when Semax is added to standard care within the first hours to days of stroke onset, with the proposed mechanism being preservation of penumbral tissue via BDNF upregulation and reduction of inflammatory gene expression.[4]
Attention and Executive Function: Smaller studies have examined Semax in attention disorders and in cognitive complaints associated with cerebrovascular disease. Reported effects include improvement in attention span, working memory tasks, and reaction time. The mechanistic rationale rests on dopaminergic modulation in prefrontal circuits combined with BDNF-mediated synaptic plasticity, though the clinical evidence base outside Russia remains limited and trials have generally been small and open-label.[3]
Optic Nerve and Retinal Applications: Semax has also been studied in optic neuropathies, where intranasal administration is proposed to deliver neurotrophic support to retinal ganglion cells via the same nose-to-brain pathway that supplies the forebrain. Evidence remains preliminary.
Safety Profile
Semax has been used clinically in Russia for over three decades with a generally favorable tolerability profile. Because it lacks ACTH 1–3 melanocortin activity, it does not stimulate the HPA axis or raise cortisol — a distinguishing safety feature relative to full-length ACTH analogs. Reported adverse effects in clinical use have generally been limited to local nasal irritation at the site of administration.[1]
Important caveats: most safety data come from Russian clinical registries and trials that have not been independently replicated to Western regulatory standards. Long-term effects of sustained BDNF/TrkB upregulation in humans are not well characterized. BDNF signaling has complex effects on neuronal excitability, and concerns about pro-epileptogenic potential of chronic TrkB activation have been raised in preclinical literature, though no clinical signal of seizure provocation has been reported in stroke trials. Drug-drug interactions, particularly with dopaminergic and serotonergic agents, are not well studied.
Semax vs Other Cognitive Approaches
vs Stimulants (Methylphenidate, Amphetamine): Classical stimulants act primarily as dopamine and norepinephrine reuptake inhibitors or releasers, producing immediate effects on attention but with tolerance, cardiovascular load, and abuse potential. Semax modulates dopaminergic tone indirectly and adds a neurotrophic dimension absent in stimulants, but lacks the robust, replicated efficacy data that support methylphenidate in ADHD.
vs Cerebrolysin: Cerebrolysin is a porcine-brain-derived neuropeptide preparation used in similar clinical indications (stroke, vascular cognitive impairment), with proposed BDNF-like activity. Semax offers a defined single-molecule alternative with characterized sequence and synthesis, avoiding the batch variability inherent to tissue-derived preparations.
vs Direct BDNF Approaches: Recombinant BDNF itself crosses the blood-brain barrier poorly and has failed in clinical neurodegeneration trials. Small-molecule TrkB agonists (e.g., 7,8-dihydroxyflavone) have shown preclinical promise but remain investigational. Semax’s approach — using a small, stable peptide to induce endogenous BDNF expression — sidesteps the delivery problem that has limited direct neurotrophin therapy.[5]
vs Selank: Selank, also developed at the Institute of Molecular Genetics, is a related Russian heptapeptide derived from tuftsin with anxiolytic and immunomodulatory effects. The two peptides are often discussed together but target distinct pathways — Semax emphasizes neurotrophic and dopaminergic effects, Selank emphasizes GABAergic and anxiolytic activity.
Summary
Semax occupies an unusual position in the peptide landscape: a clinically used drug with a defined sequence, three decades of human exposure, and a plausible mechanism centered on rapid BDNF upregulation — yet largely unfamiliar to Western clinicians because the bulk of its clinical literature is Russian. The mechanistic rationale is coherent and the safety record from registry use is reassuring, but rigorous, blinded, multicenter trials by Western regulatory standards remain sparse. For clinicians and researchers, Semax is best understood as a mechanistically interesting tool for studying BDNF-mediated cognitive effects, with clinical applications that remain promising but require further independent validation.
References
- Kaplan AYa, et al. “Synthetic ACTH analogue Semax displays nootropic-like activity in humans.” Neuroscience Research Communications. 1996;19(2):115-123.
- Dolotov OV, et al. “Semax, an analog of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.” Journal of Neurochemistry. 2006;97 Suppl 1:82-86.
- Eremin KO, et al. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochemical Research. 2005;30(12):1493-1500.
- Gusev EI, et al. “Neuroprotective effects of Semax in acute ischemic stroke.” Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2005;105(Suppl 13):3-9.
- Medvedeva EV, et al. “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.” BMC Genomics. 2014;15:228.
